Effect of cinnamon biscuits enriched with vitamin D on migraine headaches

Investigating the effect of cinnamon biscuits enriched with vitamin D compared to simple biscuits on the intensity, duration and frequency of migraine attacks and inflammatory indices in people suffering from migraine headaches: a randomized, controlled, double-blind clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240212060963N1

Enrollment

Registered

2024-04-17

Start date

2024-05-10

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine headache. Migraine with aura

Interventions

Intervention 1: Intervention group: They receive 3 cinnamon biscuits enriched with vitamin D (contains 1800 mg of cinnamon and 2000 IU of vitamin D) as a snack daily for 10 weeks. Intervention 2: Con

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Willingness to cooperate in research suffering from migraine disease with a definite doctor's diagnosis Age above 18 years People with a body mass index less than 30 (not being obese)

Exclusion criteria

Exclusion criteria: Allergy and sensitivity to cinnamon Suffering from infectious diseases in the past month Taking antibiotics in the past month Being hospitalized in the past month Taking any herbal or medicinal supplements effective on migraine Taking excessive headache tranquilizer Following special food regimens Having diabetes (due to the need to consume biscuits during the study period) Taking vitamin D supplements Being pregnant Breastfeeding

Design outcomes

Primary

Measure	Time frame
Frequency of headache attacks. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (10 weeks after the start of the intervention). Method of measurement: Interview with patients.;Duration of headache. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (10 weeks after the start of the intervention). Method of measurement: Interview with patients.;Migraine headache intensity. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (10 weeks after the start of the intervention). Method of measurement: Based on Visual Analogue Scale (VAS).;Interleukin-6 level. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (10 weeks after the start of the intervention). Method of measurement: ELISA Kit.;Nitric oxide (NO) level. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (10 weeks after the start of the intervention). Method of measurement: ELISA Kit.	—

Measure

Time frame

Frequency of headache attacks. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (10 weeks after the start of the intervention). Method of measurement: Interview with patients.;Duration of headache. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (10 weeks after the start of the intervention). Method of measurement: Interview with patients.;Migraine headache intensity. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (10 weeks after the start of the intervention). Method of measurement: Based on Visual Analogue Scale (VAS).;Interleukin-6 level. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (10 weeks after the start of the intervention). Method of measurement: ELISA Kit.;Nitric oxide (NO) level. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (10 weeks after the start of the intervention). Method of measurement: ELISA Kit.

—

Secondary

Measure	Time frame
Sleep quality score. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (10 weeks after the start of the intervention). Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDonya Arjmandfard

Shiraz University of Medical Sciences

donya.arjmand9777@gmail.com+98 71 3725 8099

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026